Collegium Pharmaceutical Inc (COLL)vsTakeda Pharmaceutical Co Ltd ADR (TAK)
COLL
Collegium Pharmaceutical Inc
$24.95
+0.56%
HEALTHCARE · Cap: $770.98M
TAK
Takeda Pharmaceutical Co Ltd ADR
$21.12
+1.34%
HEALTHCARE · Cap: $67.16B
Smart Verdict
WallStSmart Research — data-driven comparison
Takeda Pharmaceutical Co Ltd ADR generates 575626% more annual revenue ($4.69T vs $815.19M). COLL leads profitability with a 4.7% profit margin vs 0.9%. TAK appears more attractively valued with a PEG of 0.48. COLL earns a higher WallStSmart Score of 58/100 (C).
COLL
Buy58
out of 100
Grade: C
TAK
Buy56
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+88.3%
Fair Value
$384.11
Current Price
$24.95
$359.16 discount
Intrinsic value data unavailable for TAK.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Reasonable price relative to book value
Strong operational efficiency at 22.9%
Growing faster than its price suggests
Reasonable price relative to book value
Generating 212.6B in free cash flow
Large-cap with strong market position
Strong operational efficiency at 24.5%
Areas to Watch
3.3% revenue growth
Smaller company, higher risk/reward
4.7% margin — thin
Earnings declined 29.0%
ROE of 5.2% — below average capital efficiency
0.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 9.8%
Comparative Analysis Report
WallStSmart ResearchBull Case : COLL
The strongest argument for COLL centers on PEG Ratio, Price/Book, Operating Margin. PEG of 0.72 suggests the stock is reasonably priced for its growth.
Bull Case : TAK
The strongest argument for TAK centers on PEG Ratio, Price/Book, Free Cash Flow. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bear Case : COLL
The primary concerns for COLL are Revenue Growth, Market Cap, Profit Margin. Debt-to-equity of 2.75 is elevated, increasing financial risk. Thin 4.7% margins leave little buffer for downturns.
Bear Case : TAK
The primary concerns for TAK are Return on Equity, Profit Margin, P/E Ratio. A P/E of 300.3x leaves little room for execution misses. Thin 0.9% margins leave little buffer for downturns.
Key Dynamics to Monitor
COLL carries more volatility with a beta of 0.73 — expect wider price swings.
TAK is growing revenue faster at 6.7% — sustainability is the question.
TAK generates stronger free cash flow (212.6B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.
Bottom Line
COLL scores higher overall (58/100 vs 56/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Collegium Pharmaceutical Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and markets pain management medications. The company is headquartered in Stoughton, Massachusetts.
Takeda Pharmaceutical Co Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture and marketing of pharmaceuticals, over-the-counter drugs and quasi-drug consumer products, and other health care products. The company is headquartered in Tokyo, Japan.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?